The week in pharma: action, reaction and insight – week to May 10, 2024

By Barbara Obstoj-Cardwell. Editor

Deal-making news last week included Italian family-owned Chiesi Farmaceutici announcing a licensing agreement with USA-based Gossamer Bio for the latter’s pulmonary hypertension candidate seralutinib worth up to $486 million. Among other news of note, the US Food and Drug Administration (FDA) plans to hold and advisory committee meeting on June 10 to review US Pharma major Eli Lilly’s Alzheimer’s disease candidate donanemab. Flagship Pioneering announced the launch of another start-up, Prologue Medicines, with $50 million financing to develop protein therapies. Gilead Science’s Kite unit and partner Arcellx updated on their development of investigational multiple myeloma drug anitocabtagene autoleucel.

Chiesi collab with Gossamer encouraging and alleviates funding concerns